Show simple item record

dc.contributor.authorOpat, S.
dc.contributor.authorTedeschi, A.
dc.contributor.authorLinton, Kim M
dc.contributor.authorMcKay, P.
dc.contributor.authorHu, B.
dc.contributor.authorChan, H.
dc.contributor.authorJin, J.
dc.contributor.authorSobieraj-Teague, M.
dc.contributor.authorZinzani, P. L.
dc.contributor.authorColeman, M.
dc.contributor.authorThieblemont, C.
dc.contributor.authorBrowett, P.
dc.contributor.authorKe, X.
dc.contributor.authorSun, M.
dc.contributor.authorMarcus, R.
dc.contributor.authorPortell, C. A.
dc.contributor.authorArdeshna, K.
dc.contributor.authorBijou, F.
dc.contributor.authorWalker, P.
dc.contributor.authorHawkes, E. A.
dc.contributor.authorMapp, S.
dc.contributor.authorHo, S. J.
dc.contributor.authorTalaulikar, D.
dc.contributor.authorZhou, K. S.
dc.contributor.authorCo, M.
dc.contributor.authorLi, X.
dc.contributor.authorZhou, W.
dc.contributor.authorCappellini, M.
dc.contributor.authorTankersley, C.
dc.contributor.authorHuang, J.
dc.contributor.authorTrotman, J.
dc.date.accessioned2021-09-30T11:56:15Z
dc.date.available2021-09-30T11:56:15Z
dc.date.issued2021en
dc.identifier.citationOpat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, et al. The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clin Cancer Res. 2021 Sep 15;clincanres.1704.2021.en
dc.identifier.pmid34526366en
dc.identifier.doi10.1158/1078-0432.Ccr-21-1704en
dc.identifier.urihttp://hdl.handle.net/10541/624653
dc.description.abstractPurpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relapsed/refractory (R/R) MZL. Experimental design: Patients with R/R MZL were enrolled in the phase 2 MAGNOLIA (BGB-3111-214) study. The primary endpoint was overall response rate (ORR) as determined by an independent review committee (IRC) based on the Lugano 2014 classification. Results: Sixty-eight patients were enrolled. After a median follow-up of 15.7 months (range, 1.6 to 21.9 months), the IRC-assessed ORR was 68.2% and complete response (CR) was 25.8%. The ORR by investigator assessment was 74.2%, and the CR rate was 25.8%. The median duration of response (DOR) and median progression-free survival (PFS) by independent review was not reached. The IRC-assessed DOR rate at 12 months was 93.0%, and IRC-assessed PFS rate was 82.5% at both 12 and 15 months.with the majority of adverse events (AEs) being grade 1 or 2. The most common AEs were diarrhea (22.1%), contusion (20.6%), and constipation (14.7%). Atrial fibrillation/flutter was reported in two patients; one patient had grade 3 hypertension. No patient experienced major hemorrhage. In total, four patients discontinued treatment due to AEs, of which was considered treatment-related by the investigators. Conclusions: Zanubrutinib demonstrated high ORR and CR rate with durable disease control and a favorable safety profile in patients with R/R MZL.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.Ccr-21-1704en
dc.titleThe Magnolia Trial: Zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphomaen
dc.typeArticleen
dc.contributor.departmentClinical Haematology, Monash Health Department of Hematology, Niguarda Hospitalen
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record